Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (178)	10/26/2000 2:39:18 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 724

another one, from 12/17/98....... New Brunswick Scientific Co., Inc. Acquires Inceltech EDISON, N.J., Dec. 17 /PRNewswire/ -- New Brunswick Scientific Co., Inc. (NBS) (Nasdaq: NBSC) today announced that it had acquired the assets and business of Inceltech, a well known manufacturer of fermentors and cell culture bioreactors located in Toulouse, France. Inceltech has primarily served the European market with laboratory and pilot scale equipment since its founding in 1988 by Dr. Henri Blachere, an eminent French Chemical Engineer, who will remain with the Company in a technical liaison capacity. Ezra Weisman, President and CEO of NBS said: "The acquisition of Inceltech adds a new dimension to NBS by providing the Company with a European based facility which enhances our ability to more efficiently serve the important European market." Gerry Burgers, Managing Director of NBS BV and NBS Sarl, the Company's Benelux and French operations added: "We are committed to continue strengthening our sales, service and technical support capabilities in Europe. The acquisition of Inceltech is another milestone in NBS' development to better serve the European market with state-of-the-art bioprocess equipment and enhanced technical support." New Brunswick Scientific Co., Inc. designs and manufactures a wide variety of research equipment and scientific instruments for the life sciences. The Company, through DGI BioTechnologies, its majority-owned drug lead discovery operation, is also developing a proprietary process which is expected to result in the discovery of novel therapeutics by generating biologically active drug leads for known pharmaceutical targets. This press release includes statements which may constitute forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. This information may involve risks and uncertainties including without limitation, risks relating to the development by DGI of its technology, that could cause actual results to differ materially from the forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. SOURCE New Brunswick Scientific Co., Inc. Web Site: nbsc.com CONTACT: Samuel Eichenbaum, Vice President, Finance of New Brunswick Scientific Co., Inc., 732-287-1200, ext. 2239, or same@nbsc.com